US 9127056
Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
granted A61KA61K2039/505A61P
Quick answer
US patent 9127056 (Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 41
- CPC classes
- A61K, A61K2039/505, A61P, A61P35/00